Status
Conditions
Treatments
About
The primary objective of this study is to describe the frequency and characteristics of pregnancy outcomes and maternal complications among participants exposed to Ultomiris and to describe the frequency and characteristics of selected fetal/neonatal/infant outcomes in utero, at birth, and through 1 year of age after exposure in utero or via breastmilk.
Full description
This observational study will collect prospective and retrospective data in participants exposed to Ultomiris during pregnancy and/or breastfeeding to assess risk of maternal complications, adverse effects on the developing fetus, and adverse effects on the infant.
Enrollment
Sex
Volunteers
Inclusion criteria
Exclusion criteria
Loading...
Central trial contact
Alexion Pharmaceuticals, Inc. (Sponsor)
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal